S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
S&P 500   3,372.85 (-0.02%)
DOW   27,931.02 (+0.12%)
QQQ   272.16 (-0.12%)
AAPL   459.63 (-0.09%)
MSFT   208.90 (+0.10%)
FB   261.24 (-0.02%)
GOOGL   1,504.63 (-0.79%)
AMZN   3,148.02 (-0.41%)
NVDA   462.56 (+1.06%)
CGC   17.19 (-0.75%)
BABA   253.97 (+0.10%)
TSLA   1,650.71 (+1.83%)
GE   6.66 (+0.91%)
MU   45.60 (-1.17%)
AMD   81.30 (-0.66%)
T   30.01 (+0.33%)
F   7.04 (+0.14%)
ACB   10.69 (+5.01%)
GILD   68.50 (+0.47%)
NFLX   482.68 (+0.28%)
DIS   130.53 (-0.33%)
BAC   26.47 (+0.46%)
BA   178.08 (+1.92%)
Log in

NASDAQ:CLLSCellectis Stock Price, Forecast & News

$17.12
+0.13 (+0.77 %)
(As of 08/14/2020 04:00 PM ET)
Add
Compare
Today's Range
$16.79
Now: $17.12
$17.14
50-Day Range
$15.70
MA: $17.40
$19.05
52-Week Range
$7.32
Now: $17.12
$21.97
Volume4,688 shs
Average Volume170,410 shs
Market Capitalization$727.02 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm. It is also developing UCARTCLL1 to treat AML; ALLO-819 for treating AML; UCARTCS1 for the treatment of multiple myeloma (MM); and ALLO-715 to treat MM. In addition, the company produces high oleic soybean oil, other soybean products, and fiber wheat. It has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; Cornell University; Dana Farber Cancer Institute; and H. Lee Moffitt Cancer Center. Cellectis S.A. was founded in 1999 and is based in Paris, France.
Read More
Cellectis logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.24 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLLS
CUSIPN/A
Phone33-1-81-69-16-00

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$22.99 million
Book Value$8.37 per share

Profitability

Net Income$-102,090,000.00

Miscellaneous

Employees161
Market Cap$727.02 million
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$17.12
+0.13 (+0.77 %)
(As of 08/14/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CLLS News and Ratings via Email

Sign-up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Cellectis (NASDAQ:CLLS) Frequently Asked Questions

How has Cellectis' stock been impacted by Coronavirus?

Cellectis' stock was trading at $11.43 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, CLLS shares have increased by 49.8% and is now trading at $17.12.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Cellectis?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectis in the last year. There are currently 1 sell rating, 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Cellectis
.

When is Cellectis' next earnings date?

Cellectis is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for Cellectis
.

How were Cellectis' earnings last quarter?

Cellectis SA (NASDAQ:CLLS) released its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.59) by $1.06. The biotechnology company earned $51.91 million during the quarter, compared to the consensus estimate of $21.07 million. Cellectis had a negative return on equity of 18.00% and a negative net margin of 89.50%.
View Cellectis' earnings history
.

What price target have analysts set for CLLS?

7 analysts have issued 1 year price objectives for Cellectis' shares. Their forecasts range from $11.00 to $73.00. On average, they anticipate Cellectis' stock price to reach $32.17 in the next twelve months. This suggests a possible upside of 87.9% from the stock's current price.
View analysts' price targets for Cellectis
.

Has Cellectis been receiving favorable news coverage?

News articles about CLLS stock have trended somewhat negative on Friday, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellectis earned a media sentiment score of -1.3 on InfoTrie's scale. They also assigned news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.
View the latest news about Cellectis
.

Are investors shorting Cellectis?

Cellectis saw a increase in short interest in the month of June. As of June 30th, there was short interest totaling 359,300 shares, an increase of 39.9% from the June 15th total of 256,900 shares. Based on an average daily trading volume, of 216,100 shares, the short-interest ratio is presently 1.7 days. Currently, 0.9% of the shares of the stock are sold short.
View Cellectis' Short Interest
.

Who are some of Cellectis' key competitors?

What other stocks do shareholders of Cellectis own?

Who are Cellectis' key executives?

Cellectis' management team includes the following people:
  • Dr. André Choulika, Co-Founder, Chairman & CEO (Age 54)
  • Dr. David J. D. Sourdive, Co-Founder, Deputy CEO, Exec. VP of Technical Operations & Director (Age 52)
  • Mr. Eric Dutang, Chief Financial Officer (Age 45)
  • Ms. Elsy Boglioli, Chief Operating Officer (Age 37)
  • Mr. Jean Charles Epinat, Chief Technological Officer

When did Cellectis IPO?

(CLLS) raised $129 million in an initial public offering (IPO) on Wednesday, March 25th 2015. The company issued 3,500,000 shares at a price of $36.83 per share. BofA Merrill Lynch, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Oppenheimer was co-manager.

What is Cellectis' stock symbol?

Cellectis trades on the NASDAQ under the ticker symbol "CLLS."

Who are Cellectis' major shareholders?

Cellectis' stock is owned by a number of retail and institutional investors. Top institutional investors include FMR LLC (2.53%), Sumitomo Mitsui Trust Holdings Inc. (1.73%), Prosight Management LP (0.65%), Hudson Bay Capital Management LP (0.38%), New York State Common Retirement Fund (0.25%) and Vident Investment Advisory LLC (0.20%).

Which institutional investors are selling Cellectis stock?

CLLS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Sumitomo Mitsui Trust Holdings Inc., Bank of America Corp DE, Hudson Bay Capital Management LP, UBS Group AG, WS Management Lllp, Vident Investment Advisory LLC, and Vident Investment Advisory LLC.

Which institutional investors are buying Cellectis stock?

CLLS stock was acquired by a variety of institutional investors in the last quarter, including Prosight Management LP, Ikarian Capital LLC, Marshall Wace LLP, Marshall Wace North America L.P., RMB Capital Management LLC, Exchange Traded Concepts LLC, Princeton Capital Management LLC, and Mitsubishi UFJ Kokusai Asset Management Co. Ltd..

How do I buy shares of Cellectis?

Shares of CLLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cellectis' stock price today?

One share of CLLS stock can currently be purchased for approximately $17.12.

How big of a company is Cellectis?

Cellectis has a market capitalization of $727.02 million and generates $22.99 million in revenue each year. The biotechnology company earns $-102,090,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis. Cellectis employs 161 workers across the globe.

What is Cellectis' official website?

The official website for Cellectis is www.cellectis.com.

How can I contact Cellectis?

Cellectis' mailing address is 8 RUE DE LA CROIX JARRY, PARIS I0, 75013. The biotechnology company can be reached via phone at 33-1-81-69-16-00 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.